CFTR and cystic fibrosis: A great challenge in 2020 remains to accurately assess the disease liability of CFTR variants in the appropriate clinical context and to determine whether a variant should be reported as disease-causing, whether a genotype is compatible with the phenotype or which phenotype is compatible with the genotype identified in the context of NBS for CF, and whether a variant should be considered for genetic counseling purposes.